These substances shall target metastasizing and drug-resistant tumors more specifically and selectively. Qurient will successively enter the tested substances into preclinical and clinical trials in order to use them in the future for drugs. The Max Planck researchers hope that if the experiments and clinical trials are successful, a drug based on the new active substances could be on the market by the end of the decade.
To activate the Axl kinase and transmit its signal to the cell nucleus, a signal substance (blue) has to bind externally and the energy carrier ATP (green) internally. The inhibitors (orange) prevent a transmission of the signal by blocking the ATP binding site.
Picture: Axel Ullrich/Copyright: MPI of Biochemistry
According to the World Health Organization (WHO), cancer causes about 7.6 million deaths per year, making it the second leading cause of death in the world after cardiovascular disease. Most cancer patients die of the disease because tumor cells spread to other sites in the body and form new tumors, so-called metastases. Therefore, there is a growing need for effective drugs. The new substances, which are the research focus of the three cooperation partners, belong to the family of highly specific Axl kinase inhibitors. In the research department headed by Axel Ullrich at the MPI of Biochemistry, the scientists Pjotr Knyazev and Robert Torka have been conducting research on the protein Axl kinase and its inhibitors for more than ten years.
The Axl kinase is a receptor protein that is found on the surface of many cell types. It recognizes specific signal substances that play a critical role in the survival and migration of cells. The researchers showed that fewer metastases develop when the Axl kinase is inactivated. In many aggressive types of cancer the Axl kinase is present at too high levels and is thus hyperactive. For this reason, the cells are constantly stimulated to grow or migrate.
“If we block the Axl kinase, we can prevent the cancer cells from migrating and forming new metastases,” said Robert Torka, explaining the effect of the new substances. The target that the inhibitors attack is located in the interior of the cell, at the Axl kinase domain. After the appropriate signaling substance is bound externally, an energy carrier (ATP) must additionally dock to the receptor internally before the signal can be transmitted to the cell nucleus. The new substances prevent the ATP from binding and the receptor from becoming activated and thus prevent the signal from reaching the cell nucleus. All Axl kinase-dependent processes are therefore blocked in the cancer cell.
Various groups of such inhibitors have already been patented at the MPI of Biochemistry. To make the individual substances even more effective against particularly aggressive, metastasizing tumors, it was necessary to generate chemical variants. The Lead Discovery Center GmbH (LDC) assumed this part of the cooperation. For example, the LCD scientists altered the substances so that they were more soluble. The researchers at the MPI of Biochemistry then tested the variants on different cancer cell lines derived from the lung, breast or pancreas e.g. for tolerance, dosage or efficacy in combination with other active substances.
The Qurient Company will successively bring the substances to preclinical and clinical trials, in order to use them later as drugs. To continue to optimize the agents further, the scientists of the MPI of Biochemistry and the LDC are participating with tests and experiments for an additional year of collaboration. Afterwards both partners take over a consulting function during the whole development process. “Our common goal is to make tumor treatments more selective and targeted to the tumor cells. The new substances are a step in the right direction,” said Pjotr Knyazev, scientist in the Department of Molecular Biology at the MPI of Biochemistry. [VS]
ContactProf. Dr. Axel Ullrich
Anja Konschak | Max-Planck-Institut
Make way for the mini flying machines
21.03.2018 | American Chemical Society
New 4-D printer could reshape the world we live in
21.03.2018 | American Chemical Society
In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.
Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...
Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.
They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...
A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
21.03.2018 | Physics and Astronomy
21.03.2018 | Materials Sciences
21.03.2018 | Life Sciences